Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Adolescent Girls in Russian Federation
| Autor: | Alla V. Rudakova, Susanna M. Kharit, Lyudmila V. Lyalina, Alla S. Lisianskaya, Svetlana A. Protsenko, Irina V. Mikheeva, Aleksandr N. Uskov, Yurii V. Lobzin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Cervical cancer
education.field_of_study Vaginal cancer Pediatrics medicine.medical_specialty Cost effectiveness business.industry cervical cancer Population HPV infection virus diseases RM1-950 medicine.disease vaccination Genital warts Vaccination human papilloma virus medicine cost-effectiveness Anal cancer Therapeutics. Pharmacology markov model education business |
| Zdroj: | Pediatričeskaâ Farmakologiâ, Vol 14, Iss 6, Pp 494-500 (2018) |
| ISSN: | 2500-3089 1727-5776 |
| Popis: | The human papillomavirus (HPV) infection is one of the major risk factor of development of genital warts, a cervical dysplasia, a cervical cancer, and also some other oncologic diseases. The usage of quadrivalent HPV vaccine in girls reduces the corresponding case rate and the mortality significantly. The objective of this study is to analyze the cost-effectiveness of quadrivalent HPV vaccination cases of 12-year-old girls in Russian Federation. Methods . A Markov model is used on the basis of epidemiological data in Russian Federation. In base case the cost-effectiveness was estimated from societal perspective. We assumed that the effect of vaccination remains throughout all life. The analysis is performed for survival of 12-year-old girls. We considered only effect in the vaccinated population. Costs for therapy of the diseases associated with HPV infection corresponded to compulsory health insurance rates across St. Petersburg for 2017. Costs and life expectancy have been discounted for 3.5% a year. Results . Quadrivalent HPV vaccination of 12-year-old girls in Russian Federation will allow to prevent counting on 100 000 the vaccinated persons 2918 cases of genital warts, 5095 cases of cervical dysplasia, 893 cases of invasive cervical cancer, 56 cases of vulvar cancer, 18 cases of vaginal cancer, 13 cases of anal cancer, 7 cases of oropharyngeal cancer. The vaccination will provide cost reduction, caused by HPV-associated diseases, for 453.9 million rubles on 100 000 vaccinated, and 86.5% of the predicted prevented costs will be caused by decrease in incidence of cervical cancer, 9% — cervical dysplasia, 2.9% — genital warts. The quadrivalent HPV vaccination is associated with an incremental cost-effectiveness ratio (ICER) of 247 560 rubles per quality adjusted life-year (QALY) and 334 200 rubles per life-year gained (LYG). Thus, in both cases, cost effectiveness of rotavirus vaccination per 1 QALY will not exceed the generally accepted threshold willingness-to-pay equal to three times the gross domestic product in Russia (2016 — 1.76 million RUB). Conclusions. Quadrivalent HPV vaccination of girls prior to the beginning of sex life could be considered in Russian Federation as an economically effective technology for preventing HPV-associated diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|